Key result
Patients with microvascular angina exhibited increased levels of NO synthesis inhibitors and reduced NO synthase expression in red blood cells, indicating impaired NO production capacity.
Why the study?
Does the metabolic profile of the NO synthetic pathway and oxidative stress differ in patients with microvascular angina compared to CAD patients and healthy controls?
Observational
Does the metabolic profile of the NO synthetic pathway and oxidative stress differ in patients with microvascular angina compared to CAD patients and healthy controls?
Patients with microvascular angina exhibit impaired red blood cell capacity to produce nitric oxide and increased oxidative stress, similar to but less extreme than patients with obstructive coronary artery disease.
Hypothesis-generating for NO pathway assessment in microvascular angina; leaves open therapeutic implications pending prospective validation.
A decreased nitric oxide (NO) bioavailability and an increased oxidative stress play a pivotal role in different cardiovascular pathologies. As red blood cells (RBCs) participate in NO formation in the bloodstream, the aim of this study was to outline the metabolic profile of L-arginine (Arg)/NO pathway and of oxidative stress status in RBCs and in plasma of patients with microvascular angina (MVA), investigating similarities and differences with respect to coronary artery disease (CAD) patients or healthy controls (Ctrl). Analytes involved in Arg/NO pathway and the ratio of oxidized and reduced forms of glutathione were measured by LC-MS/MS. The arginase and the NO synthase (NOS) expression were evaluated by immunofluorescence staining. RBCs from MVA patients show increased levels of NO synthesis inhibitors, parallel to that found in plasma, and a reduction of NO synthase expression. When summary scores were computed, both patient groups were associated with a positive oxidative score and a negative NO score, with the CAD group located in a more extreme position with respect to Ctrl. This finding points out to an impairment of the capacity of RBCs to produce NO in a pathological condition characterized mostly by alterations at the microvascular bed with no significant coronary stenosis.
No takes yet. Share an insight, caveat, or question.
Porro et al. (2014) conducted an observational in Microvascular angina. Microvascular angina (exposure) vs. Coronary artery disease (CAD) patients and healthy controls was evaluated on Metabolic profile of L-arginine/NO pathway and oxidative stress status in RBCs and plasma. Patients with microvascular angina exhibited increased levels of NO synthesis inhibitors and reduced NO synthase expression in red blood cells, indicating impaired NO production capacity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: